ES2721781T3 - Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa - Google Patents

Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa Download PDF

Info

Publication number
ES2721781T3
ES2721781T3 ES16717470T ES16717470T ES2721781T3 ES 2721781 T3 ES2721781 T3 ES 2721781T3 ES 16717470 T ES16717470 T ES 16717470T ES 16717470 T ES16717470 T ES 16717470T ES 2721781 T3 ES2721781 T3 ES 2721781T3
Authority
ES
Spain
Prior art keywords
convertase
measure
factor
protease activity
complement pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16717470T
Other languages
English (en)
Inventor
Krista Johnson
Christen Forbes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2721781T3 publication Critical patent/ES2721781T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/537—Protease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Abstract

Un método para medir la actividad proteasa de C3 convertasa que comprende las etapas de: a. unir covalentemente biotina a C3b para producir C3b biotinilado (bio-C3b); b. unir C3b biotinilado a una proteína de unión a biotina inmovilizada sobre una fase sólida; c. incubar el C3b biotinilado inmovilizado, factor D y factor B en un tampón para formar una C3 convertasa; d. transferir C3 al tampón para escindir C3 con la convertasa para formar C3a y C3b; y e. medir la cantidad de C3a con un inmunoensayo, en donde cada uno de los componentes individuales, bio-C3b, factor B, factor D y C3 son sustancialmente homogéneos.
ES16717470T 2015-03-25 2016-03-28 Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa Active ES2721781T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562138235P 2015-03-25 2015-03-25
PCT/IB2016/051750 WO2016151557A1 (en) 2015-03-25 2016-03-28 A method for measuring the protease activity of c5 convertase of the alternative complement pathway

Publications (1)

Publication Number Publication Date
ES2721781T3 true ES2721781T3 (es) 2019-08-05

Family

ID=55795010

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16717470T Active ES2721781T3 (es) 2015-03-25 2016-03-28 Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa

Country Status (5)

Country Link
US (2) US20180087087A1 (es)
EP (1) EP3274468B1 (es)
ES (1) ES2721781T3 (es)
TR (1) TR201904903T4 (es)
WO (1) WO2016151557A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190877A1 (en) * 2018-03-26 2019-10-03 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement c3 convertase

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4582810A (en) 1983-09-30 1986-04-15 Becton, Dickinson And Company Immuno-agglutination particle suspensions
DE3640412A1 (de) 1986-11-26 1988-06-09 Boehringer Mannheim Gmbh Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
EP0598877B1 (en) 1992-06-09 1999-07-28 Hoppe Ag Latch and lockset system
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6221657B1 (en) 1995-09-08 2001-04-24 Imutran Limited Modified human C3 DNA sequences and vectors
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
DE19724787A1 (de) 1997-06-06 1998-12-10 Biotez Berlin Buch Gmbh Bioche Streptavidin/Avidin beschichtete Oberflächen
US7255858B2 (en) 2001-08-10 2007-08-14 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
JP4768224B2 (ja) 2001-09-10 2011-09-07 メソ スケイル テクノロジーズ，エルエルシー １つの試料について複数の測定を実施する方法及び装置
US7078061B2 (en) 2002-12-26 2006-07-18 Meso Scale Technologies Llc Methods, compositions and kits for biomarker extraction
US7319525B2 (en) 2003-11-06 2008-01-15 Fortebio, Inc. Fiber-optic assay apparatus based on phase-shift interferometry
EP2195024B1 (en) 2007-08-27 2016-10-05 NovelMed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
US20110263451A1 (en) 2008-09-30 2011-10-27 Genentech, Inc Biological markers predictive of rheumatoid arthritis response to lymphotoxin antagonists
US9939448B2 (en) 2010-01-06 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Methods for detecting insulin autoantibody
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies

Also Published As

Publication number Publication date
US20180087087A1 (en) 2018-03-29
EP3274468B1 (en) 2019-02-20
WO2016151557A1 (en) 2016-09-29
US20230265481A1 (en) 2023-08-24
TR201904903T4 (tr) 2019-05-21
EP3274468A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CU20150023A7 (es) Anticuerpos anti-mcam y metodos de uso asociados
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
UY37758A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
AR092968A1 (es) Anticuerpos monoclonales y metodos de deteccion para enzimas que confieren resistencia a la fosfinotricina-n-acetil-transferasa
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
PE20190229A1 (es) Anticuerpos anti-fcrn
MA52742A (fr) Anticorps bispécifiques dll3-cd3
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
EA201890611A1 (ru) Библиотеки модульных полипептидов и способы их получения и применения
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
BR112015022034A2 (pt) Camundongo, célula isolada, embrião de camundongo, hibridoma, uso de um camundongo, e, método para fabricar um anticorpo
DK3041862T3 (da) Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
TR201904997T4 (tr) Modifikasyona bağlı aktivite tahlilleri.
CL2015000422A1 (es) Metodo de produccion de postre congelado, y mezcla estable de ingredientes para dicho postre.
MA49250A (fr) Nouveaux anticorps anti-cd3
BR112018008673A2 (pt) métodos para medir a atividade do fator d e para determinar a potência de um inibidor do fator d, método de triagem para um inibidor do fator d e kits
ES2721781T3 (es) Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa
DK3003385T3 (da) Antistofsammensætning og buffersystem til denne